- Home
- VABK vs CHRS Comparison
VABK vs CHRS Comparison
Compare VABK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VABK
- CHRS
- Stock Information
- Founded
- VABK 1998
- CHRS 2010
- Country
- VABK United States
- CHRS United States
- Employees
- VABK N/A
- CHRS N/A
- Industry
- VABK Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VABK Finance
- CHRS Health Care
- Exchange
- VABK Nasdaq
- CHRS Nasdaq
- Market Cap
- VABK 203.8M
- CHRS 186.0M
- IPO Year
- VABK N/A
- CHRS 2014
- Fundamental
- Price
- VABK $39.57
- CHRS $1.35
- Analyst Decision
- VABK
- CHRS Strong Buy
- Analyst Count
- VABK 0
- CHRS 4
- Target Price
- VABK N/A
- CHRS $4.51
- AVG Volume (30 Days)
- VABK 10.3K
- CHRS 1.1M
- Earning Date
- VABK 10-23-2025
- CHRS 11-06-2025
- Dividend Yield
- VABK 3.69%
- CHRS N/A
- EPS Growth
- VABK 14.21
- CHRS N/A
- EPS
- VABK 3.30
- CHRS 1.33
- Revenue
- VABK $56,512,000.00
- CHRS $277,728,000.00
- Revenue This Year
- VABK N/A
- CHRS N/A
- Revenue Next Year
- VABK N/A
- CHRS $109.48
- P/E Ratio
- VABK $11.82
- CHRS $2.56
- Revenue Growth
- VABK 10.39
- CHRS 152.07
- 52 Week Low
- VABK $33.66
- CHRS $0.70
- 52 Week High
- VABK $44.57
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- VABK 50.45
- CHRS 33.62
- Support Level
- VABK $39.10
- CHRS $1.39
- Resistance Level
- VABK $40.03
- CHRS $1.61
- Average True Range (ATR)
- VABK 0.84
- CHRS 0.11
- MACD
- VABK 0.02
- CHRS -0.05
- Stochastic Oscillator
- VABK 47.87
- CHRS 8.49
About VABK Virginia National Bankshares Corporation
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.